Last Updated : March 10, 2021
Details
FilesGeneric Name:
tofacitinib
Project Status:
Complete
Therapeutic Area:
Ulcerative colitis
Manufacturer:
Pfizer Canada Inc.
Call for patient/clinician input open:
Brand Name:
Xeljanz
Project Line:
Reimbursement Review
Project Number:
SR0572-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a TNFa inhibitor.
Submission Type:
Initial
Fee Schedule:
Schedule B
Indications:
Indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a TNFa inhibitor.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient input posted | May 22, 2018 |
| Patient group input closed | July 11, 2018 |
| Clarification:
- Patient input submission received from the Gastrointestinal Society |
|
| Patient input summary sent for review to patient input groups | July 17, 2018 |
| Patient group comments on input summary closed | July 24, 2018 |
| Clarification:
- Patient input summary feedback received |
|
| Submission received | June 27, 2018 |
| Submission accepted | July 12, 2018 |
| Review initiated | July 13, 2018 |
| Draft CADTH review report(s) sent to sponsor | October 10, 2018 |
| Comments from sponsor on draft CADTH review report(s) received | October 19, 2018 |
| Redaction requests from sponsor on draft CADTH review report(s) received | October 26, 2018 |
| CADTH review team's comments on draft CADTH review report(s) sent to sponsor | November 09, 2018 |
| Canadian Drug Expert Committee (CDEC) meeting | November 21, 2018 |
| CDEC recommendation & redacted CADTH review report(s) sent to sponsor and drug plans | December 04, 2018 |
| Embargo period ended and validation of redacted CADTH review report(s) received | December 18, 2018 |
| Clarification:
- Reconsideration requested |
|
| Sponsor's request for reconsideration placed on CDEC agenda | February 20, 2019 |
| CDEC Final Recommendation issued to sponsor and drug plans | February 27, 2019 |
| CDEC Final Recommendation posted | March 01, 2019 |
| Final CADTH review report(s) and patient input posted | March 21, 2019 |
Files
Last Updated : March 10, 2021